The latest announcement is out from Inhibikase Therapeutics ( (IKT) ).
On February 21, 2025, Inhibikase Therapeutics completed a merger with CorHepta Pharmaceuticals, making CorHepta a wholly-owned subsidiary. The transaction involved a $15 million payment in the form of company shares, with some shares contingent on future milestones. The company also announced leadership changes, appointing Chris Cabell as President and Head of Research and Development, and Vincent Aurentz to the Board of Directors, aiming to enhance its strategic positioning in the biopharmaceutical industry.
More about Inhibikase Therapeutics
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary diseases, with a lead product IkT-001, an oral prodrug of imatinib mesylate, targeting pulmonary arterial hypertension (PAH).
YTD Price Performance: -9.73%
Average Trading Volume: 281,961
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $206M
See more insights into IKT stock on TipRanks’ Stock Analysis page.